Der Wirkmechanismus
Optune Lua ist eine einzigartige Behandlungsmodalität, die physikalische Kräfte nutzt, um Krebszellen abtöten zu können.1
TTFields sind elektrische Wechselfelder mit einer spezifischen Frequenz, die es ermöglichen, die Krebszellteilung selektiv zu stören.1,13
Da gesunde Zellen andere Eigenschaften haben als Krebszellen (einschließlich Teilungsrate, Morphologie und elektrische Eigenschaften), werden sie von Optune Lua in der Regel geschont.6-11
Siehe den Überlebensvorteil bei mNSCLC
mNSCLC, metastasiertes nicht-kleinzelliges Lungenkarzinom; TTFields, Tumor Treating Fields.
Referenzen: 1. Optune Lua. Instructions for Use for non small cell lung cancer. Novocure; 2023. 2. Gera N, Yang A, Holtzman TS, Lee SX, Wong ET, Swanson KD. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. PLoS One. 2015;10(5):1-20. doi:10.1371/journal.pone.0125269 3. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:1-16. doi:10.1038/srep18046 4. Voloshin T, Kaynan N, Davidi S, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. Cancer Immunol Immunother. 2020;69(7):1191-1204. doi:10.1007/s00262-020-02534-7 5. Barsheshet Y, Voloshin T, Brant B, et al. Tumor treating fields (TTFields) concomitant with immune checkpoint inhibitors are therapeutically effective in non-small cell lung cancer (NSCLC) in vivo model. Int J Mol Sci. 2022;23(22):1-15. doi:10.3390/ijms232214073 6. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol. 2021;97(8):1044-1054. doi:10.1080/09553002. 2020.1837984 7. Cooper GM. The development and causes of cancer. In: The Cell: A Molecular Approach. 2nd ed. Sinauer Associates; 2000:chap 15. Accessed January 18, 2024. https://www.ncbi.nlm.nih.gov/books/NBK9963/ 8. Baba AI, Câtoi C. Tumor cell morphology. In: Comparative Oncology. The Publishing House of the Romanian Academy; 2007:chap 3. Accessed January 18, 2024. https://www.ncbi.nlm.nih.gov/books/NBK9553/ 9. Trainito CI, Sweeney DC, Čemažar J, et al. Characterization of sequentially-staged cancer cells using electrorotation. PLoS One. 2019;14(9):1-18. doi:10.1371/journal.pone.0222289 10. Haemmerich D, Schutt DJ, Wright AW, Webster JG, Mahvi DM. Electrical conductivity measurement of excised human metastatic liver tumours before and after thermal ablation. Physiol Meas. 2009;30(5):459-466. doi:10.1088/0967-3334/30/5/003 11. Ahmad MA, (IEEE SM), Al Natour Z, Mustafa F, Rizvi TA. Electrical characterization of normal and cancer cells. IEEE Access. 2018;6:25979-25986. doi:10.1109/ACCESS.2018.2830883 12. Voloshin T, Schneiderman RS, Volodin A, et al. Tumor treating fields (TTFields) hinder cancer cell motility through regulation of microtubule and actin dynamics. Cancers (Basel). 2020;12(10):1-18. doi:10.3390/cancers12103016 13. Kirson ED et al. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 2004;61(9):3288-3295.